Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or pal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Rossi, Lorenzo, Biagioni, Chiara, McCartney, Amelia, Migliaccio, Ilenia, Curigliano, Giuseppe, Sanna, Giuseppina, Moretti, Erica, Minisini, Alessandro M., Cinieri, Saverio, Tondini, Carlo, Arpino, Grazia, Bernardo, Antonio, Martignetti, Angelo, Risi, Emanuela, Pestrin, Marta, Boni, Luca, Benelli, Matteo, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6542028/
https://ncbi.nlm.nih.gov/pubmed/31142370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1149-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars